Pronutria is developing a new class of healthcare products, therapeutic nutrients, intended to treat or prevent major human diseases. The intersection of health maintenance and disease treatment has grown more important, not only with the recognition of fundamental pathophysiology of important diseases such as sarcopenia and diabetes, but also with governmental regulation including Obamacare. The company, founded by VentureLabs, has undertaken the first ever systematic analysis of food, developed fundamental metrics around the properties of its components, and developed a computational approach to identify single factors with preferred health, function, and taste properties. Pronutria has leveraged its platform to rapidly produce candidates in key disease areas, and has set the groundwork to transform multiple areas of medicine, including several for which drugs alone have proven insufficient.
Noubar Afeyan is Chairman of the Board of Directors. David Berry is a Co-Founder, Chief Scientific Officer and on the Board of Directors.